13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002005245
Total reported value
$4.9B
$4.9B
110 檔
14.3%
According to the latest 13F quarterly dataset, Siren, L.L.C. managed an equity portfolio of $4.9B at the end of Q2 2025, spanning 110 distinct U.S. exchange-listed positions.
During Q2 2025, Siren, L.L.C.'s portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SRRK | Scholar Rock Holding CORP | Stock-Other | 16.95% | -4.09% | — | |
| 2 | KYMR | Kymera Therapeutics Inc | Stock-Other | 7.74% | -0.55% | +5.80% | |
| 3 | ONC | Beone Medicines Ltd-adr | Stock-Other | 6.39% | -1.15% | +2.27% | |
| 4 | IRON | Disc Medicine Inc | Stock-Other | 3.01% | -0.43% | +2.57% | |
| 5 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 2.51% | -0.84% | — | |
| 6 | BCAX | Bicara Therapeutics Inc | Stock-Other | 2.51% | +0.17% | +59.68% | |
| 7 | DYN | Dyne Therapeutics Inc | Stock-Other | 2.38% | -0.16% | +77.94% | |
| 8 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 2.35% | -1.16% | EXIT | |
| 9 | ✓ | Merus N V | Stock-Other | 2.32% | — | -18.21% | |
| 10 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 2.31% | — | — | |
| 11 | ASND | Ascendis Pharma A/S | Stock-Other | 2.20% | — | -14.41% | |
| 12 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 2.18% | +0.02% | — | |
| 13 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 2.14% | -1.25% | +86.29% | |
| 14 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 2.03% | — | -35.75% | |
| 15 | LXRX | Lexicon Pharmaceuticals Inc | Stock-Other | 1.90% | +0.23% | — | |
| 16 | TBLA | Taboola.com Ltd. | Stock-Other | 1.89% | -0.01% | — | |
| 17 | SLDB | Solid Biosciences Inc | Stock-Other | 1.87% | +0.02% | — | |
| 18 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 1.79% | +0.41% | +66.52% | |
| 19 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 1.63% | — | — | |
| 20 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 1.34% | +0.80% | +47.64% | |
| 21 | APGE | Apogee Therapeutics Inc | Stock-Other | 1.34% | — | — | |
| 22 | STOK | Stoke Therapeutics Inc | Stock-Other | 1.32% | -0.48% | — | |
| 23 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 1.32% | +0.27% | +69.07% | |
| 24 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 1.32% | -0.52% | +10.92% | |
| 25 | WVE | Wave Life Sciences Ltd. | Stock-Other | 1.24% | -0.49% | EXIT | |
| 26 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 1.24% | — | — | |
| 27 | SEPN | Septerna Inc | Stock-Other | 1.20% | -0.04% | — | |
| 28 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 1.12% | — | -37.54% | |
| 29 | TRVI | Trevi Therapeutics Inc | Stock-Other | 1.11% | +0.08% | +37.54% | |
| 30 | TNGX | Tango Therapeutics Inc | Stock-Other | 0.89% | +0.63% | +31.16% | |
| 31 | AKRO | Akero Therapeutics Inc | Stock-Other | 0.88% | — | — | |
| 32 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 0.87% | +0.31% | +4.36% | |
| 33 | AVBP | Arrivent Biopharma Inc | Stock-Other | 0.79% | — | — | |
| 34 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 0.72% | -0.20% | EXIT | |
| 35 | RCUS | Arcus Biosciences Inc | Stock-Other | 0.68% | -0.29% | — | |
| 36 | IHS | IHS Holding Limited | Stock-Other | 0.68% | — | — | |
| 37 | AMZN | Amazon.com Inc | Stock-Consumer Disc | 0.64% | -0.11% | — | |
| 38 | DNLI | Denali Therapeutics Inc | Stock-Other | 0.59% | -0.01% | — | |
| 39 | ERAS | Erasca Inc | Stock-Other | 0.58% | -0.81% | — | |
| 40 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 0.53% | -0.39% | — | |
| 41 | RELY | Remitly Global Inc | Stock-Other | 0.50% | +0.03% | +5.10% | |
| 42 | PCVX | Vaxcyte Inc | Stock-Other | 0.50% | — | — | |
| 43 | CRWD | Crowdstrike Holdings Inc - A | Stock-Tech | 0.49% | -0.10% | -26.00% | |
| 44 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 0.47% | +0.23% | — | |
| 45 | GOOGL | Alphabet Inc-cl A | Stock-Comm Services | 0.46% | +0.13% | — | |
| 46 | UPB | Upstream Bio Inc | Stock-Other | 0.45% | — | — | |
| 47 | SEER | Seer Inc | Stock-Other | 0.44% | -0.03% | — | |
| 48 | MSFT | Microsoft CORP | Stock-Tech | 0.42% | +0.04% | -43.33% | |
| 49 | NVDA | Nvidia CORP | Stock-Tech | 0.41% | -0.05% | +12.50% | |
| 50 | IONQ | Ionq Inc | Stock-Tech | 0.38% | +0.04% | — |
According to official SEC Form 13F filings, Siren, L.L.C. reported a total U.S. public equity portfolio value of $4.9B across 110 disclosed positions in Q2 2025.
During Q2 2025, Siren, L.L.C.'s top holdings by market value included SRRK (16.9%)、KYMR (7.7%)、ONC (6.4%). The largest single position, SRRK, represented 16.9% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including SRRK, KYMR, ONC) accounted for 14.3% of total reported equity market value during Q2 2025.
In Q2 2025, Siren, L.L.C. made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.